Sagimet Biosciences Inc. (SGMT)
NASDAQ: SGMT · Real-Time Price · USD
9.83
+1.47 (17.58%)
At close: Jun 24, 2025, 4:00 PM
9.92
+0.09 (0.92%)
Pre-market: Jun 25, 2025, 5:55 AM EDT
Sagimet Biosciences Stock Forecast
Stock Price Forecast
The 6 analysts that cover Sagimet Biosciences stock have a consensus rating of "Strong Buy" and an average price target of $23.17, which forecasts a 135.71% increase in the stock price over the next year. The lowest target is $6 and the highest is $32.
Price Target: $23.17 (+135.71%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Sagimet Biosciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 7 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Jones Trading | Jones Trading | Strong Buy Maintains $15 → $27 | Strong Buy | Maintains | $15 → $27 | +174.67% | Jun 6, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $32 | Strong Buy | Reiterates | $32 | +225.53% | Mar 13, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $32 | Strong Buy | Reiterates | $32 | +225.53% | Mar 11, 2025 |
| Jones Trading | Jones Trading | Strong Buy Initiates $42 | Strong Buy | Initiates | $42 | +327.26% | Jan 27, 2025 |
| Oppenheimer | Oppenheimer | Buy Initiates $30 | Buy | Initiates | $30 | +205.19% | Dec 6, 2024 |
Financial Forecast
Revenue This Year
1.28M
Revenue Next Year
n/a
from 1.28M
EPS This Year
-2.24
from -1.45
EPS Next Year
-2.85
from -2.24
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 10.5M | n/a | 70.4M | ||
| Avg | 1.3M | n/a | 12.5M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.39 | -1.33 | -1.27 | ||
| Avg | -2.24 | -2.85 | -3.17 | ||
| Low | -3.49 | -4.08 | -5.05 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.